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Abstract: Current treatment protocols for postoperative
pain are beset by either the short duration of the anesthetic
effect or requirement of hospitalization of the patients. We
reported herein a novel treatment by applying to the surgi-
cal site a biodegradable microparticle–gel system for pro-
longed and localized release of encapsulated anesthetic
drugs. In a previous publication, lidocaine-loaded poly(D,L-
lactic acid) microspheres were fabricated and their formula-
tions were optimized. In vitro characterization of these
lidocaine-loaded microspheres, however, revealed a short-
coming of this system; that is, microspheres tend to fuse
physically. Fusion of the microspheres could hinder their
clinical applications, as it would clog the needle. In this
article, we demonstrated that fabricating microspheres with
high molecular weight (60 KDa) poly(lactic-co-glycolic
acid) would increase the glass transition temperature of the
microspheres after lidocaine loading, thereby increasing
their mechanical stability and eliminating their fusion dur-
ing storage. Such microspheres containing 31% (w/w) lido-
caine in the presence or absence of 25% (w/v) poloxamer
407 gel were then evaluated in vivo by monitoring the sen-
sory and motor functions of the rats after sciatic nerve block,
using the previously established hot-plate and weight-bear-
ing testing methods. Results showed that microspheres for-
mulated with poloxamer 407 gel yielded the longest dura-
tion of sensory and motor block for a period of
approximately 8.5 h, compared to 5 h by microspheres in
saline, 5 h by lidocaine in poloxamer 407 gel, and 2 h by
lidocaine in saline. This study suggests that the micro-
sphere–gel system containing lidocaine could potentially be
applied clinically to the treatment of postoperative pain.
© 2004 Wiley Periodicals, Inc. J Biomed Mater Res 70A:
459–466, 2004
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INTRODUCTION
Due to the short duration of anesthetic effects pro-
vided by currently existing postsurgery pain treat-
ment, we have explored the possibility of utilizing a
sustained-release microsphere formulation to over-
come such problems. In a previous poly(D,L-lactide)
(PLA, MW 20,000)-based lidocaine-loaded micro-
sphere system was successfully fabricated. In vitro
characterization of these microspheres showed a sus-
tained release of lidocaine over a period of more than
4 days without the initial drug burst release.1 In ad-
dition, these lidocaine-loaded microspheres displayed
a reasonably rapid degradation kinetics (4 weeks),
which would suit for the clinical application. Despite
promises, in vitro studies also revealed a shortcoming
of this system that could hinder its clinical application;
that is, microspheres displayed a strong tendency to
fuse during storage, which would therefore clog the
needle during administration of the microspheres. In
this article, we demonstrated that by utilizing high
molecular weight poly(lactic-co-glycolic acid) (PLGA,
MW 60,000 daltons) or PLA (130,000 daltons)
would resolve this problem. Because PLGA would
degrade faster than PLA, it was used to fabricate the
microspheres. In an attempt to further prolong the
anesthetic effect, 25% of poloxamer 407 (PO407) solu-
tion was formulated with these PLGA microspheres,
because the aqueous PO407 solution at concentrations
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above 20% exhibited a temperature-dependent gela-
tion behavior.2 Therefore, the incorporated PO407 so-
lution would remain in an aqueous state at 4°C during
administration but change to a gel state at the surgical
site when temperature was raised to 37°C, retarding
lidocaine release from the microspheres. In vivo testing
of these formulated PO407–PLGA microspheres was
conducted using a sciatic nerve blocked rat model.3
The sensory and motor functions of the rats were
assessed by the hot-plate and weight-bearing tests,
respectively. Comparison was made with formula-




Poloxamer 407 (PO407), lidocaine hydrochloride, lido-
caine (Lid), and sorbitan monooleate (Span 80) were pur-
chased from Sigma (St. Louis, MO). Poly(D,L-lactic acid)
(PLA, i.v. 0.4, MW 20,000 dalton) and poly(vinyl alcohol)
(PVA, MW 6,000 dalton and 80 mol % hydrolyzed) were
obtained from Polyscience Inc. (Warrington, PA). Poly(D,L-
lactic acid) (PLA, i.v. 0.73, MW 130,000 dalton) and
poly(lactic-co-glycolic acid) (PLGA, i.v. 0.75, MW 80,000
dalton) were purchased from Alkermes (Cambridge, MA).
Preparation of lidocaine-loaded PLGA
microspheres
Lidocaine-loaded microspheres were prepared using the
oil/water solvent-evaporation method.4 Briefly, 800 mg
PLGA, 800 mg lidocaine (free base), and 120 mg Span 80
were added to 2 mL methylene chloride. The organic phase
was stirred for 3 h to form a homogenous solution and then
mixed with 10 mL of 0.75% (w/v) PVA aqueous solution.
After vortexing for 30 s, the mixture was sonicated for 1 min
to produce an oil/water emulsion. This emulsion was then
added to 90 mL of 0.75% (w/v) PVA aqueous solution and
after continuous stirring for 2 h to evaporate methylene
chloride, the mixture was passed through a stainless steel
sieve (pore size of 300 m) to remove large particles. The
microspheres were washed twice with ddH2O, collected by
centrifugation at 4°C, freeze dried, and then stored under
vacuum at 4°C.
Preparation of microsphere–gel formulations
The 25% (w/v) PO407 gel solution was prepared by dis-
solving an appropriate amount of PO407 in a cold 0.9%
saline solution. To prepare 2% of lidocaine  HCl in PO407
gel, an appropriate amount of lidocaine  HCl was dissolved
in 0.9% saline solution, and then cooled down to 4°C before
the addition of an appropriate amount of PO407. Micro-
sphere–PO407 gel formulation was prepared directly prior
to use by mixing an appropriate amount of the microspheres
with the PO407 gel solution at 4°C.
Characterization of microspheres
Microspheres were characterized by using scanning elec-
tron microscopy (SEM) and differential scanning calorime-
try (DSC) according to procedures described previously.1
Briefly, microspheres were carbon coated and fixed by
graphite on a stub before SEM observation.
In vitro lidocaine release
Samples were enclosed in dialysis bags (MW cutoff 
12,000 dalton) and then placed in 200 mL of 0.1 M phosphate
buffer (pH 7.4). The buffer was shaken at 30 rpm and 37°C.
At predetermined time points, 1 mL of buffer was with-
drawn and assayed for the released lidocaine using HPLC
according to the procedures described previously.1
Animal care
Young adult male Sprague-Dawley rats weighing 310–
420 g each were obtained from Taconic Farms (German-
town, NY) and housed in groups in a 6 a.m. to 6 p.m.
light–dark cycle. Animals care was in compliance with pro-
tocols approved by the Animal Care and Use Committee at
the Massachusetts Institute of Technology, and with the
Principles of Laboratory Animal Care published by the Na-
tional Institutes of Health. Each rat was injected with its
designated sample once only.
Sciatic nerve blockade, neurobehavioral testing,
and data analysis
To prepare the sciatic nerve blocked animals, male
Sprague-Dawley rats were injected with samples at the sci-
atic nerve according to an established procedure.3 In brief,
animals were anesthetized in isoflurane:oxygen, and sam-
ples were then injected through a 23-gauge needle intro-
duced posteromedial to the greater trochanter and advanced
in an anteromedial direction until bone was contacted.5
Samples were maintained on ice until the time of injection
because of the reverse thermal gelation property of PO407.
The left leg of the rat was always used for blocks, with the
right leg serving as a control. Unless otherwise stated, six
rats were included in each experimental group.
Nociceptive block was assessed by a modified hotplate
test, in which the hindpaws of the rat were exposed to a
hotplate at 56°C and the time (thermal latency) until the rat
withdrew its paws was recorded.6 If the paw of the rat
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remained on the hotplate over 12 s without self-withdrawal,
it was then removed to avoid injury. The data for nocicep-
tive block were reported in terms of thermal latency (a
measure of the degree of analgesia) and duration of block;
the later was defined as the time required for thermal la-
tency to return to 7 s (i.e., 50% of maximal latency given a
baseline of approximately 2 s).
Motor strength was assessed by allowing the animal to
bear weight on one hindpaw at a time, and then by measur-
ing the maximum weight generated without its ankle touch-
ing the balance. The duration of motor block was defined as
the time for weight bearing to return halfway to normal
from maximal block.
For each group of animals, the latency at any given time
point and the duration of block were expressed as means 
standard deviations. Comparisons between groups were
performed using the Student’s t-test.
RESULTS
Preparation and characterization of the
microspheres
In a previous article,1 we demonstrated that sus-
tained lidocaine release could be achieved by increas-
ing the Lid/PLA (MW 20,000) ratio, Span80/PLA
ratio, and PLA concentration. However, microspheres
employed in these studies showed a tendency to fuse
automatically. To overcome this fusion problem, high
molecular weight PLA (MW 130,000) or PLGA (MW
80,000) was used in the current investigation to fab-
ricate the microspheres. These newly prepared micro-
spheres were found to be relatively stable and remain
separated. To confirm the hypothesis that fusion was
caused by a reduction in Tg due to the plasticizing
effect of lidocaine on PLA, Tg of the microspheres
made by high MW PLA or PLGA polymers with and
without lidocaine loading were examined using DSC
(see Fig. 1). Surprisingly, both types of microspheres
displayed an increased Tg in the presence of lidocaine
in contrast to the decreased Tg observed previously for
microspheres made with low MW PLA polymer.1 The
reason that the plasticizing effect of lidocaine was not
observed with the high MW polymers remains unclear
at this moment.
Because PLGA degrades much faster than PLA due
to its amorphous structure, PLGA-based microspheres
were used in current studies. The same procedures
established previously in modifying the microsphere
formulations1 by utilizing the highest PLGA concen-
tration, 15% Span80/PLGA ratio, and the highest pos-
sible lidocaine loading, was followed. The morphol-
ogy of these microspheres was examined by SEM (see
Fig. 2), and the size of most particles were in the range
between 1 and 100 m.
In vitro release of lidocaine from various
formulations
Lidocaine release from several different formula-
tions was examined. As shown in Figure 3, lidocaine
was released most rapidly from the formulation con-
taining 1.3 mL of 2% (w/v%) lidocaine  HCl in 0.9%
saline solution, followed by that containing 2% of
lidocaine  HCl in 1.3 mL of 25% (w/v%) PO407 gel.
Formulations containing 75 mg microspheres in 1.3
mL of 0.9% saline solution and in 1.3 mL of 25%
(w/v%) PO407 gel exhibited the slowest lidocaine re-
lease. Microspheres used in the formulations con-
tained 31% (w/w) lidocaine loading. Therefore, all the
four studied formulations contained the same lido-
caine dose of 23 mg (not counting the weight of HCl in
lidocaine  HCl).
Effectiveness of the formulations on sciatic
nerve block
Rats were injected at the sciatic nerve with one of four
formulations (containing the same lidocaine dose of 23
mg): lidocaine  HCl (2%) in saline (0.9%); lidocaine  HCl
(2%) in PO407 gel (25%); 75 mg microspheres (31% lido-
Figure 1. DSC diagrams of (a) PLA (MW  20,000), Tg 
50°C; (b) PLA (MW 20,000) of 11% lidocaine loading, Tg 
41°C; (c) PLA (MW 130,000), Tg  47°C; (d) PLA (MW
130,000) with 27% lidocaine loading, Tg  50°C; (e) PLGA
(MW 80,000), Tg  46°C; and (f) PLGA (MW 80,000) with
31% lidocaine loading, Tg  54°C. Tg is defined as the
temperature at the onset of the peaks.
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Figure 2. Morphology observed by SEM of the PLGA microspheres containing 31% lidocaine.
Figure 3. In vitro release (n  3) of (F) 2% lidocaine  HCl in 0.9% saline solution, (Œ) 2% lidocaine  HCl in 25% (w/v%)
PO407 gel, (■) 31% lidocaine microspheres in 0.9% saline solution, and () 31% lidocaine microspheres in 25% PO407 gel.
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caine loading) in saline (0.9%), and 75 mg microspheres
(31% lidocaine loading) in PO407 gel (25%). As shown
by results in Figure 4, all rats who received one of the
four different formulations achieved the maximal nerve
block (thermal latency  12 s) by the time of the first
testing; that is, 30 min after sample injection. However,
results in Figure 5 showed that lidocaine in PO407 gel
yielded a longer duration of sensory (271  21 min) and
motor (421  46 min) block than lidocaine in saline
(126  35 min and 124  31 min for durations of sensory
and motor block, respectively; p  0.001). This finding
suggested that the PO407 gel was able to slow the dif-
fusion of lidocaine from the sciatic nerve. Although no
statistically significant difference was observed (p 
0.048) in the duration of sensory block between lidocaine
in PO407 gel (271  21 min) and microspheres in saline
(301  25 min), the former nevertheless yielded a longer
duration of motor block (421  46 min) than the latter
(341  4 min) (p  0.001). Among the four tested formu-
lations, microspheres in PO407 gel displayed the longest
duration of motor and sensory block (429  35 min and
537  36 min, respectively; p  0.001 when compared to
the formulation of microspheres in saline). To ensure
that the nerve block resulted directly from the lidocaine,
PO407 gel without lidocaine loading was also examined
and found to produce no anesthetic effect.
Overall, motor blockade was longer than sensory
blockade in most of the formulations by the following
proportions: lidocaine in PO407 gel by 56% (p  0.001),
microspheres in saline by 13% (p  0.014), microspheres
in PO407 gel by 9% (p  0.003), except for the formula-
tion of lidocaine in saline by 0% (p  0.821).
Systemic distribution of lidocaine
To assess the degree of systemic distribution of the
drug from different formulations, all animals were
tested for functional deficits in the leg that did not
receive sample injection.7 Figure 6 showed that rats
injected with lidocaine in PO407 gel, microspheres in
Figure 4. Changes of the thermal latency (n  6) versus time of the leg injected with the four drug formulations; (F) 2%
lidocaine  HCl in 0.9% saline solution; (Œ) 2% lidocaine  HCl in 25% (w/v%) PO407 gel; (■) 31% lidocaine microspheres in
0.9% saline solution; and () 31% lidocaine microspheres in 25% PO407 gel.
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saline, or microspheres in PO407 gel yielded a thermal
latency of 2 s (baseline) from beginning to the end,
exhibiting either minimal or no contralateral deficits.
These results suggested minimal systemic distribution
of lidocaine. In contrast, rats injected with lidocaine in
saline yielded a significant increase in latency in their
uninjected leg at the time of the first observation (30
min), and such a functional deficit was gradually re-
solved over the next 2–3 h. In this regard, with only
the exception of the formulation containing lidocaine
in saline solution, the other three formulations all
appeared to achieve significant nerve block with only
minimal systemic distribution (i.e., less toxicity) of the
delivered lidocaine.
DISCUSSION
As demonstrated in Figure 5, lidocaine in PO407 gel
yielded a significantly longer duration of motor block
than that of sensory block (p  0.001) when compared
with the other formulations; a property that was not
desirable because it would result in a paralyzed limb
with full sensation. The most likely explanation for this
phenomenon was that, after the majority of lidocaine
was diffused away (when full sensation was recovered),
the PO407 gel still contained the level of lidocaine that
was sufficient enough to cause motor block but not
sensory block. Indeed, the ability of PO407 gel to with-
hold lidocaine longer than the saline solution was seen
from results in Figure 4, where it showed that it took
longer (about 6–7 h) for the thermal latency induced by
both PO407 formulations (i.e., lidocaine in PO407 gel and
microspheres in PO407 gel) to drop from maximum (12
s) to minimum (2 s) than that (about 2–4 h) by both
saline formulations (i.e., lidocaine in saline and micro-
spheres in saline). The need of a lesser amount of lido-
caine for motor block was because the large myelinated
fibers (A fibers) that mediated motor function were more
sensitive to amino-amide local anesthetics than were the
small unmyelinated fibers (C fibers) that mediated pain.
The slow diffusion of lidocaine in PO407 gel could also
Figure 5. Comparison of durations of sensory blockade versus motor blockade (n  6); (F) 2% lidocaine  HCl in 0.9% saline
solution; (Œ) 2% lidocaine  HCl in 25% (w/v%) PO407 gel; (■) 31% lidocaine microspheres in 0.9% saline solution; and ()
31% lidocaine microspheres in 25% PO407 gel. Points falling above the diagonal line bisecting the graph represent a relative
motor predominance in nerve blockade, whereas those falling below the diagonal line indicate a sensory predominance.
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account for the significantly longer motor block with
lidocaine in PO407 gel formulation than microspheres in
saline formulation, while both formulations yielded the
same sensory blockade. On the other hand, motor block
by lidocaine in saline did not last any longer than sen-
sory block (p  0.821); the result of a fast diffusion (or
systemic distribution) of the delivered lidocaine.
Bupivacaine has been shown in clinical practice to
have a slower onset and a longer duration of anes-
thetic effect than lidocaine. In a previous report,8 it
was observed that 4 out of 10 rats treated with PLGA
microspheres containing a dose of 38 mg bupivacaine
did not achieve the maximal nerve block (thermal
latency  12 s) by the time of the first measurement
(30 min). In our study, however, all rats treated with
microspheres containing a dose of 23 mg lidocaine
achieved the maximal nerve block within 30 min.
These findings suggested that the lidocaine micro-
spheres prepared in our study would immediately
relieve patients from pain after surgery compared
with the bupivacaine microspheres that would yield a
slower onset even at a higher dose. Other investigators
reported a 6-h duration of nerve block when treating
the rats with PLGA microspheres containing 50 mg
bupivacaine.9 Comparing to their results, our formu-
lation of microspheres containing only 23 mg lido-
caine yielded a comparable duration of 5 h despite the
fact that lidocaine possessed an intrinsically shorter
duration than bupivacaine. Of greater promise is that
microspheres in PO407 gel with only 23 mg lidocaine
yielded an 8-h duration of nerve block.
Based on the assumption that the optimal lidocaine
Figure 6. Changes of the thermal latency (n  6) over time of the control leg (right leg) after the left leg was injected with
the four formulations; (F) 2% lidocaine  HCl in 0.9% saline solution; (Œ) 2% lidocaine  HCl in 25% (w/v%) PO407 gel; (■)
31% lidocaine microspheres in 0.9% saline solution; and () 31% lidocaine microspheres in 25% PO407 gel.
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dose for rat and human is weight proportional, 15 g
microspheres would be needed for a 70-kg individual
because 75 mg microspheres was used in the rat (0.35
kg in weight). A dose of more than 15 g microspheres
would be both unrealistic and impractical in clinical
practice. However, this assumption may not be correct
judged by results from our animal studies. In the
current study, 23 mg lidocaine solution was shown to
achieve a 2-h anesthetic effect in rats, whereas in real
clinical practice, only 100 mg lidocaine solution would
be needed to achieve a 1–2 h anesthetic effect in hu-
mans.10 Based on this observation, the dose difference
between human and rat is only about 5–10 folds rather
than the estimated 200 times. This discrepancy in dose
could be due to the difference between localized drug
delivery and systemic drug administration. In appli-
cation of the microsphere–gel system, lidocaine was
administered locally and in direct contact with the
target nerve areas to provide an immediate effect,
whereas the assumption of a weight-proportion in
dose should only be applicable when the drug was
administered systemically. Because only a 5–10-fold
increase in dose would be required from rats to hu-
mans, 750 mg of the microspheres in PO407 gel would
deem to be sufficient in yielding an anesthetic effect of
longer than 8 h. In this regard, a substantially longer
anesthetic effect should be observed if the micro-
sphere dose is increased up to the maximal applicable
dose of 15 g for humans.
In conclusion, sustained release of lidocaine from
the PLGA microparticle–PO407 gel could clinically
provide a prolonged anesthetic effect with a rapid
onset yet without significant systemic toxicity. Efforts
to further optimize this system to achieve a clinically
relevant approach for effective postsurgical pain treat-
ment are continued in our laboratories.
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